spondylitis ankylosing
Recently Published Documents
Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Colitis, Ulcerative,Crohn Disease,Hidradenitis Suppurativa, Date of authorisation: 13/02/2020, Status: Authorised
Human medicines European public assessment report (EPAR): Erelzi, etanercept, Arthritis, Psoriatic,Psoriasis,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid,Spondylitis, Ankylosing, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Erelzi, etanercept, Arthritis, Psoriatic,Psoriasis,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid,Spondylitis, Ankylosing, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 36, Status: Authorised
Human medicines European public assessment report (EPAR): Kromeya, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Colitis, Ulcerative,Crohn Disease, Date of authorisation: 02/04/2019, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Hidradenitis Suppurativa,Spondylitis, Ankylosing,Psoriasis,Arthritis, Juvenile Rheumatoid,Uveitis, Date of authorisation: 26/07/2018, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Inflectra, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 09/09/2013, Revision: 23, Status: Authorised
Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Hidradenitis Suppurativa,Psoriasis,Crohn Disease,Uveitis,Arthritis, Rheumatoid,Arthritis,Colitis, Ulcerative,Spondylitis, Ankylosing,Arthritis, Psoriatic, Date of authorisation: 24/08/2017, Revision: 10, Status: Authorised